Ovarian Cancer
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
Cyclacel Pharmaceuticals Doses First Patient in CDK2/9 Inhibitor Basket Trial
The firm will evaluate fadraciclib as a monotherapy for patients with certain solid tumors and lymphomas in the Phase I/II registration-directed trial.
Eli Lilly Grants Acrivon Therapeutics Worldwide License to Develop DNA Damage Inhibitor Prexasertib
Acrivon will advance the drug, now dubbed ACR-368, in various tumor types using its OncoSignature tests to identify best responders.
Tango Therapeutics to Go Public on Nasdaq Through SPAC
The combined company is expected to receive $353 million in gross proceeds, which will help advance several of Tango's precision oncology drug candidates.
NICE Recommends Lynparza, Avastin Combination in Ovarian Cancer Through Cancer Drugs Fund
While more data are collected, the CDF can provide the regimen to advanced, HRD-positive ovarian cancer patients after first-line platinum chemo and bevacizumab.